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Abstract
Members of the heterochromatin protein 1 family (HP1α, β and γ) are mostly associated
with heterochromatin and play important roles in gene regulation and DNA damage re-
sponse. Altered expression of individual HP1 subtype has profound impacts on cell prolifer-
ation and tumorigenesis. We analyzed the expression profile of HP1 family by data mining
using a published microarray data set coupled with retrospective immunohistochemistry
analyses of archived breast cancer biospecimens. We found that the patient group overex-
pressing HP1βmRNA is associated with poorly differentiated breast tumors and with a
significantly lower survival rate. Immunohistochemical staining against HP1α, HP1β and
HP1γ shows that respective HP1 expression level is frequently altered in breast cancers.
57.4 - 60.1% of samples examined showed high HP1β expression and 39.9 - 42.6 % of ex-
amined tumors showed no or low expression of each HP1 subtype. Interestingly, compara-
tive analysis on HP1 expression profile and breast cancer markers revealed a positive
correlation between the respective expression level of all three HP1 subtypes and Ki-67, a
cell proliferation and well-known breast cancer marker. To explore the effect of individual
HP1 on PARP inhibitor therapy for breast cancer, MCF7 breast cancer cells and individually
HP1-depleted MCF7 cells were treated with PARP inhibitor ABT-888 with or without carbo-
platin. Notably, HP1β-knockdown cells are hypersensitive to the PARP inhibitor ABT-888
alone and its combination with carboplatin. In summary, while increased HP1β expression
is associated with the poor prognosis in breast cancer, compromised HP1β abundance
may serve as a useful predictive marker for chemotherapy, including PARP inhibitors
against breast cancer.
Introduction
Breast cancer is one of the leading causes of death in the United States and worldwide. Early di-
agnosis and effective use of adjuvant therapies are required to improve patient survival [1, 2].
Prognostic factors that are frequently used for making clinical decisions in breast cancer are
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age, tumor size, status of lymph nodes, histological types of the tumor, pathological grade, and
hormone receptor status. However, more biomarkers are needed for therapy and prediction of
outcome because human breast cancers are diverse in their genetic nature and their response
to therapy. Recently, many groups have tried to identify gene signatures of breast cancer pa-
tients [3, 4]. These gene signatures can lead to more accurate clinical decisions for cancer pa-
tients [5]. Breast cancer can be classified into several groups depending on their expressions of
biomarkers and pathology of breast cancer specimens. The most common molecular markers
for breast cancers include estrogen receptor (ER), progesterone receptor (PR), HER2/neu,
EGFR, Ki-67 and others [6]. The subgroups of breast cancer include Luminal A, Luminal B,
Basal, HER2-enriched subtypes [6]. Triple negative breast cancer subtypes, which have defi-
cient expression of ER, PR and HER2/neu, usually have poor prognosis and do not respond to
hormone therapy. However, triple negative breast cancer is also a heterogeneous group, which
shows different gene signatures [7]. For example, some triple negative breast cancers have de-
fective BRCA1 genes, whereas other triple negative breast cancer patient groups have functional
BRCA1. BRCA1 is one of the most frequently mutated genes in breast cancer patients [8].
Women with germline mutations in BRCA1 have high risk of breast cancer (~80% by the age
of 70), ovarian cancer (~30–40%) and other cancers. BRCA1 is involved in maintaining geno-
mic integrity by functioning in pathways involved in DNA repair, cell cycle checkpoint control,
apoptosis, chromosome segregation and others [8]. One of the main roles of BRCA1 is to pro-
mote homologous recombination repair and G2/M cell cycle arrest during DNA damage re-
sponse. Thus, the loss of BRCA1 is frequently associated with a dramatic increase of genomic
instability and tumorigenesis. While germline BRCA1 mutations are rarely found in patients
with sporadic breast cancers, the functions of BRCA1 may be inactivated by other mechanisms,
which are often referred to as “BRCAness” [9]. One of the possible mechanisms of BRCAness
is the inactivation of BRCA1 function at the epigenetic level by DNAmethylation of the
BRCA1 promoter [9, 10].
BRCA status is also important for cancer therapy. The genomic instability of BRCA1- and
BRCA2-defective cells can be exploited for cancer therapy [11, 12]. Clinically, the genomic in-
stability phenotype of BRCA1- and BRCA2- deficient cells provided an opportunity for PARP
inhibitor treatment [12, 13]. Poly(ADP-ribose) polymerase (PARP) is involved in the repair of
DNA single strand breaks (SSBs), and failure of their repair can lead to the generation of DNA
double strand breaks (DSBs) during DNA replication. Inhibition of PARP1 leads to a large in-
crease in DSBs and to cell death in the absence of BRCA1 or 2 and/or in the absence of HR de-
pendent DSB repair [11, 12]. This is the basis for the concept that PARP inhibitors induce
synthetic lethality in HR repair deficient tumors and provides a novel strategy for cancer thera-
py, at least in breast cancer patients who have mutations in BRCA1 or BRCA2. Recent clinical
trials of a PARP inhibitor reported a partial success in cancer therapy with less severe side ef-
fects [14–16].
Previously, we found that HP1 is an important factor for the activity of BRCA1 as part of
the DNA damage response pathway [17]. In this study, we investigated the expression level of
Heterochromatin protein 1 (HP1) in breast cancer cases. HP1 binds to dimethylated and tri-
methylated histone H3 (H3K9Me2 and Me3) and associates with heterochromatin in the nu-
cleus [18, 19]. HP1 has diverse roles that include gene regulation and DNA damage response
among others [20, 21]. We have recently shown that BRCA1 is not functional in its foci forma-
tion, homologous recombination repair, or G2/M checkpoint control in the absence of HP1 ex-
pression upon DSB induction [17]. Since HP1 is an essential factor for BRCA1 function during
the DNA damage response pathway, it is possible that HP1 expression levels may be altered
during tumorigenesis. Here, we found the heterogeneous expression of all three HP1 subtypes
in breast cancer patients. We uncovered that breast cancer patients with tumors expressing
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high levels ofHP1βmRNA had less probability of survival. We also found the positive correla-
tion of HP1 expression and Ki-67 cancer marker in breast cancer samples, suggesting potential
significance of HP1 as a marker for breast cancer prognosis. Furthermore, we showed that
PARP inhibitor ABT-888 was more effective in inducing death of HP1β-deficient MCF7 breast
cancer cells. These data suggest that HP1β level could not only serve as a useful marker for
breast cancer prognosis but also as a predictive marker for PARP therapy.
Materials and Methods
Data mining on microarray dataset
A total of 10 published microarray data sets including: Ivshina (GSE4922), Chin (E-TABM-
158), Wang (GSE2034), Pawitan (GSE1456), Desmedt (GSE7390), Expo (GSE2109), Huang
[22], Bild (GSE3143), Sortiriou (GSE2990) and NKI [23] with clinical annotations were down-
loaded from the combined microarray dataset BRAVO (Biomarker recognition and validation
on-line). The NKI (Netherlands Cancer Institute)-295 set was especially selected for HP1 prog-
nostic evaluation because the probe (Agilent Technologies) for cbx1 (HP1β) is 100% identical
to previously identified sequence of cbx1 and it contains information of most gene signatures’
classification. NKI data set (295 patients analyzed, Accession number N/A) used 25,000-gene
array that comes from Agelent Technologies, which used same probers with Affymetrix HG-
U133 array.
Patient enrollment, follow-up and tissue array
Patients diagnosed with breast cancer and treated by surgical resection between January 2002
and January 2006 in the Second Affiliated Hospital of Zhejiang University (ZJU) were included
in this study. A breast cancer pathologist (F. Q.) used haematoxylin and eosin (H&E)-stained
slides, to retrospectively review the history of all cases. The clinicopathological parameters that
were evaluated included patient age at the time of diagnosis, tumor node metastasis (TNM)
stage, date of last follow-up, and overall patient survival. Exclusion included breast cancer sam-
ples from patients without a pathologic diagnosis, those with multiple cancers, or those patients
with whom contact was lost after surgery. A total of 222 breast cancer patients were included in
this study. Follow-ups were conducted for all participants and the surgery relapse and death
data were collected until 2010. Overall survival (OS) rate was calculated from the date of sur-
gery to date of death by breast cancer-associated illness. Disease-free survival (DFS) rate was
calculated from date of surgery to date of local recurrence or metastasis. If no death or relapse
occurred, the OS and DFS rates were calculated from date of surgery to September 2010. All of
the formalin-fixed, paraffin-embedded (FFPE) breast cancer tissue samples that were collected
were reassembled into multiple tissue arrays. Analysis indicated that HP1 immunohistological
signals did not correlate with storage time (likelihood, p = 0.246), indicating the storage time
did not affect the immunohistochemical outcome.
Immunohistochemistry (IHC)
HP1 protein levels in the 222 breast cancer samples were assessed by IHC with anti-HP1
antibodies (1:75 dilution); anti-HP1α (Bethyl, Abcam), anti HP1β (ab10478, Abcam) and
anti-HP1γ (ab10480, Abcam). The IHC conditions for HP1 expression determination were
pre-optimized on checkboards with multiple tissue samples. Briefly, after de-paraffinization,
pre-treatment with 3% H2O2 was used to block the endogenous peroxidase activity. The slides
were incubated with normal goat serum for 20 minutes at room temperature (RT) to block
non-specific signal, then incubated with the primary antibody for 20 minutes at RT. The array
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slides were then incubated with polymer horseradish peroxidase-labeled secondary antibodies
for 30 minutes at RT, then 3,3-Diaminobenzidine (DAB)-treated (0.05 g DAB and 100 ml 30%
H2O2 in 100 ml PBS) for 5 and 10 minutes, respectively. Each slide was counterstained with
DAKO's haematoxylin. For each IHC staining, the negative and positive checkboards were ap-
plied as quality controls. The specificity of anti-HP1 antibodies were validated by Western
analyses. HP1 staining was predominantly nucleus, and HP1 expression was assessed using a
visual grading system on the basis of the intensity of staining signals observed by light micros-
copy. Each sample was independently scored by two investigators (Y.L. and X.L.), including
one breast cancer pathologist (X.L.) using a double-blind design to avoid scoring bias. Discrep-
ancies were re-evaluated by joint review between the two readers. Less than 10% variation was
noticed among different slides.
Statistical analysis
The database was created by using MS-Access and data analysis was performed using JMP 8.0
software (SAS Institution) and GraphPad Prism 5.0 software. Group comparisons for continu-
ous data were done by t-test for independent means or 1-way ANOVA. Each cell biology ex-
periment was performed in triplicate to obtain representative means and images. Categorical
variables were compared using χ2 analysis, Fisher’s exact test or binomial test of proportions.
Kaplan-Meier analysis and a COX hazard proportional model were used to analyze overall sur-
vival and disease-free-survival. Multivariate analysis and stratification were used to reduce the
confounder’s impact on the estimation of the Hazard Ratio (HR). Statistical significant was set
as p< 0.05, two-tailed.
Apoptosis assay
Apoptotic cells were measured by FITC Annexin V Apoptosis Detection Kit I (BD Pharmin-
gen) according to manufacturer’s protocol. MCF7 cells and HP1-depleted MCF7 cells were
cultured and harvested before or after irradiation. The harvested cells were washed twice with
ice-cold PBS and then resuspended cells in 1 x Binding Buffer (0.1 M Hepes/NaOH (pH 7.4),
1.4 M NaCl, 25 mM CaCl2.) at a concentration of 1 x 10
6 cells/ml. 100 μl of cells (1 x 105 cells)
were transferred to a 5-ml culture tube and incubated with FITC-conjugated Annexin V (5 μl).
The incubated cells were incubated for 15 minutes at Room Temperature (25°C) in the dark
and 1 x Binding Buffer (400 μl) was added to each tube. The stained cells were analyzed by
flow cytometry.
Ethical statement
The protocol for the use of human tissues was reviewed and approved by the Medical Ethics
committee of the 2nd affiliated hospital, school of medicine, Zhejiang University (Zhejiang,
China) (Institutional Review Board (IRB) number 73, Approving date; Dec 12, 2012). Prior to
the study, all patients gave their written informed consent to allow us to use leftover tissue sam-
ples for scientific research. All eligible participants had received modified radical mastectomy
and the primary tumor samples were obtained from surgical specimens. The exclusion criteria
were: 1) no informed consent obtained, 2) multiple cancers, 3) lack of histological diagnosis,
and 4) no follow-up information.
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Results
HP1β/CBX1mRNA level is inversely associated with breast cancer
patient survival
Initially, we used data mining techniques to determine if the expression level of HP1β/CBX1
mRNA was associated with the outcome of breast cancer patients using a published microarray
dataset [23, 24]. Since the expression level ofHP1βmRNA is diverse in breast cancer samples,
we classified patients into four groups (0, 1, 2, 3) according to quartile of HP1βmRNA levels.
A total of 74 breast cancer patients were stratified as high expressors of HP1βmRNA (group-3)
and 221 patients were classified as low or no expressors ofHP1β (group-0, -1 or -2). Kaplan-
Meier analyses indicated thatHP1 expression was a critical prognostic indicator for both over-
all and disease-free survival for all breast cancer patients. Notably, highHP1β expressor group
(N = 74) was associated with lower DFS (disease-free survival) (p = 0.001) and OS (overall sur-
vival) (p = 0.008), when compared with lowerHP1β expressor group (Fig. 1A). The OS and
DFS time were calculated as the length of time from date of surgical operation to the date of
specific breast cancer-related death and relapse/metastasis, respectively. However, expression
of other HP1 subtype mRNAs was not analyzed in this analysis or did not affect the survival in
a statistically-significant manner. Furthermore, highHP1β expression was associated with
poorly differentiated cancer grade (Fig. 1B). High HP1β expression group displayed more ag-
gressive types of breast cancers like basal and luminal B type. However, low HP1β expressors
exhibited more low, moderately, or well-differentiated phenotypes. These suggest that HP1β
mRNA expression level may be a prognostic marker for survival of breast cancer patients.
Altered expression of HP1 proteins in breast cancer patients
SinceHP1βmRNA expression levels were significantly associated with survival of breast cancer
patients, we sought to examine the protein expression level of HP1 subtypes in breast cancer
samples by IHC staining. First, normal skin and normal breast samples were stained with
HP1β specific antibody. IHC of normal skin showed that HP1β staining is nuclear. Similarly,
IHC staining showed that HP1β in normal mammary samples also showed that HP1β is pri-
marily nuclear with a weaker expression of HP1β in the cytoplasm (Fig. 2A, upper panels).
Next, we stained 190 breast cancer samples using an anti-HP1β antibody. Fig. 2A (lower pan-
els) shows that HP1β expression patterns in breast cancer samples are diverse and altered in
most of cases. Some of the breast cancer samples showed strong nuclear HP1β levels in the nu-
cleus, whereas other samples showed lower or no HP1β signals. There are also samples that
manifest clear staining of HP1β only in the cytoplasm, but not in the nucleus (Fig. 2A, lower
panels). Therefore, HP1β is heterogeneously distributed in breast cancer samples. The breast
cancer samples were further analyzed individually and classified into four groups (0, 1, 2, 3)
based on the HP1β expression level (S1 Fig.). Accordingly, 34 (18.6%), 39 (21.3%), 58 (31.7%)
and 52 (28.4%) samples were designed to group-0, -1, -2 and -3, respectively. We then further
divided them into low HP1β expression group (0+1) and high HP1β expression group (2+3).
Overall, 60.1% of breast cancer biospecimens exhibited high HP1β (HP1β-high) levels and
39.9% of breast cancer samples showed no or low levels of HP1β (HP1β-low) (Fig. 2).
To compare the expression patterns of other HP1 subtypes, IHC staining was also per-
formed with anti-HP1α or -HP1γ antibody. Fig. 2B (upper and lower panels) shows an altered
and heterogeneous HP1α and HP1γ staining in breast cancer samples. In parallel, we further
classified high and low HP1α and HP1γ level groups based on their respective expression level.
111 (58.4%) and 109 (57.4%) tumors displayed high HP1α and HP1γ expression (S1 and
S2 Tables). Taken together, approximately 60% breast cancer patients showed high levels of at
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Fig 1. HP1βmessage abundance is associated with survival of breast cancer patients. Amicroarray database of 295 breast cancer patients (NKI-295
dataset) was analyzed andHP1βmessage signals were investigated. A. Kaplan-Meier analyses indicated thatHP1βmRNA abundance is inversely
correlated with both disease-free survival (DFS) and overall survival (OS) for breast cancer patients. B. Group of high HP1β expressors is associated with
aggressive and poorly differentiated breast cancers. Low or high HP1βmessage abundance are denoted frommicroarray database from the public
domain [23].
doi:10.1371/journal.pone.0121207.g001
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Fig 2. Levels of HP1 protein in breast cancer tissues are heterogeneous. A. Normal skin and breast
tissues were stained with an anti-HP1β antibody (upper panel). Representative examples of breast cancer
sample staining by an anti-HP1β antibody (lower panel). Depending on expression level and subcellular
localization of HP1β, cancer samples were classified to three groups. B. Comparison of expression HP1
subtypes in breast cancer samples. Three sets of 190 breast cancer tumors were stained with individual
HP1β Is a Biomarker for Breast Cancer Prognosis and Therapy
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least one HP1 subtype. Intriguingly, 82 cases (46.6%) of 176 validated stained samples by all
three antibodies showed the same IHC staining scores by antibodies recognizing three individ-
ual HP1 subtypes. Fig. 2B shows that HP1-High and HP1-Low group samples were stained (or
not) with three individual HP1 subtypes antibodies, respectively. HP1-Mixed is the group of
the breast tumors showing strong expression of only one or two HP1 subtype(s). Specifically,
133 breast cancer tumors (75.6%) showed the same groups of high or low HP1 expressors.
Only 15% of cancer samples showed a mixed expression pattern of HP1 subtypes (Fig. 2B,
HP1-Mixed). Furthermore, analysis of nuclear and cytoplasmic staining patterns showed that
HP1 proteins are strongly stained in the cytoplasm of some cancer samples. Especially, 49 cases
(27%, out of 176) of breast cancer patients showed strong cytoplasmic HP1α staining. Al-
though a significant portion of cancer tissues showed stronger HP1 cytoplasmic staining in this
study (Fig. 2), the potential roles of HP1 mis-localization in breast cancer cells remain unclear.
We have compared various cancer markers between HP1-nucleus and HP1-cytoplasm groups
(data not shown). However, the correlation of HP1 mis-localization and breast cancer tumori-
genesis has yet been established.
Positive correlation of HP1α, β and γ expression and Ki-67, a cell
proliferation marker, in breast cancer
Table 1, S1 and S2 Tables show the clinical and pathological characteristics of 190 breast cancer
patients. These include patients’ ages, tumor stages, lymph node infiltration, expression status
of ER, PR, p53, Ki-67, HER2. We divided the patient groups into the high HP1 group or the
low HP1 group according IHC scoring data. We analyzed the correlation of respective HP1
IHC signals with other breast cancer clinical and pathological markers in Table 1, S1 and S2
Tables. Notably, one common feature of our findings was the positive correlation of Ki-67 with
HP1α (p = 0.0415), HP1β (p = 0.0007) and HP1γ (p = 0.0002), respectively (Fig. 3). Our analy-
ses further indicated a significant correlation between HP1α level and several breast cancer
markers, such as age, ER status, p53 status and molecular subtypes (S1 Table). HP1γ level was
also correlated with p53 status (S2 Table). However, the HP1β signal showed significant corre-
lation especially with Ki-67 (Table 1). Since expressions of all three HP1 subtypes showed a
clear correlation with the cell proliferation marker, Ki-67, high HP1 expression probably re-
flects a group of patients with actively growing breast cancer cells. Conceivably, these analyses
suggested the abundance of all three HP1 subtypes could provide useful prognostic informa-
tion on breast cancer patients.
HP1β depleted breast cancer cells are hypersensitive to PARP inhibitor
Previously, we reported that HP1 family is required for DNA damage response primarily
through the regulation of BRCA1 function [17]. HP1-depleted cells showed defective BRCA1
foci formation, homologous recombination DNA repair and G2/M cell cycle checkpoint con-
trol in response to irradiation. As this study showed that significant populations of breast can-
cer patients have low or no expression of at least one HP1 subtype (Fig. 2), we tested the effect
of individual HP1 on PARP inhibitor therapy. To achieve this goal, MCF7 cells and individual-
ly HP1-depleted MCF7 cells (S2 Fig.) were treated with ABT-888 (Veliparib), which is one of
subtypes anti-HP1 antibodies, anti-HP1α, HP1β or HP1γ (Abcam antibodies: ab77256, ab10478, ab10480).
IHC staining patterns were compared and IHC staining scores were determined as shown in S1 Fig. Scale
bars: 100 μm. HP1-High indicates the group of tumors with abundant expression of all three HP1 subtypes.
HP1-Low is the group with no or low expression of all three HP1 subtypes. HP1-Mixed group of cancer
samples are high level expression with one or two HP1 subtypes. Representative images are shown.
doi:10.1371/journal.pone.0121207.g002
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the PARP inhibitors currently undergoing clinical evaluation [25]. MCF7 breast cancer cells
were chosen for our experimental paradigm because MCF7 harbors wild-type tumor suppres-
sor BRCA1 in addition to wild type p53, ER, and PR [26]. MCF7 cells and individually HP1-
depleted MCF7 cells were treated with vehicle or ABT-888 (20 or 200 μM) for 72 hours. The
cells were collected and stained with Annexin V and propidium iodide (PI) and analyzed by
Table 1. Correlation analyses of HP1β expression level with several molecular and pathological cancer markers.
Characteristics Total number of patients HP1β-Low (N = 74) HP1β-High (N = 113) p-value
Median age Age<49 years 83 (43.9%) 32 (43.2%) 50 (44.2%) 0.3141
Age>49 years 107 (56.1%) 42 (56.8%) 63 (56.8%)
Tumor stages T0–T1 58 (31.5%) 24 (36.4%) 32 (28.6%) 0.2818
T2–T3 123 (68.5%) 42 (63.6%) 80 (71.4%)
Lymph node N2 negative 98 (54.0%) 45 (60.1%) 56 (49.6%) 0.1301
N2 positive 92 (46.0%) 29 (39.2%) 57 (50.4%)
ER ER negative 61 (40.7%) 24 (43.6%) 37 (39.0%) 0.5737
ER positive 91 (59.3%) 31 (56.4%) 58 (61.0%)
PR PR negative 71 (47.4%) 22 (40.7%) 50 (51.0%) 0.2234
PR positive 83 (52.6%) 32 (59.3%) 48 (49.0%)
p53 p53 negative 92 (57.6%) 40 (66.7%) 51 (52.0%) 0.0693
p53 positive 67 (42.4%) 20 (33.3%) 47 (48.0%)
Ki-67 Ki-67 negative 72 (44.5%) 39 (60.9%) 34 (34.0%) 0.0007
Ki-67 positive 94 (55.5%) 25 (39.1%) 66 (66.0%)
HER2 HER2 negative 129 (82.2%) 45 (83.3%) 80 (81.6%) 0.069
HER2 positive 27 (17.8%) 9 (16.7%) 18 (18.4%)
Molecular type Luminal A 50 (35.5%) 23 (47.9%) 26 (28.9%) 0.1179
Luminal B 52 (37.0%) 15 (31.3%) 36 (40.0%)
TNBC 26 (18.8%) 8 (16.7%) 18 (20.0%)
HER2+ 12 (8.7%) 2 (4.2%) 10 (11.1%)
doi:10.1371/journal.pone.0121207.t001
Fig 3. Positive correlation of HP1 and Ki-67 levels in breast cancer. Levels of HP1α, HP1β and HP1γ IHC signal were positively correlated with Ki-67
levels in breast cancer patients. 0 indicates no or low expression and 1 denotes high expression of respective HP1 subtype, as shown in Fig. 2, and Ki-67
level, respectively.
doi:10.1371/journal.pone.0121207.g003
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flow cytometry. MCF7 cells with wild type BRCA1 were relatively resistant to PARP inhibitor
treatment (Fig. 4A). However, treatment of ABT-888 (20 μM) induced high level of apoptosis
in HP1β-depleted MCF7 cells. Although treatment ABT-888 (200 μM) barely increased the
Annexin V-positive MCF7 population, it markedly increased Annexin V-positive, presumably
apoptotic, HP1α-, β- or γ-knockdown MCF7 cells (Fig. 4B). Notably, the cell death (double
stained population by PI and Annexin V) in HP1β-depleted cells was 10 times higher than that
of MCF7 cells (Fig. 4A). HP1α- or γ- depleted MCF7 cells were also hypersensitive to ABT-
888. This suggests that PARP inhibitor ABT-888 can effectively target HP1-deficient, especially
HP1β-deficient, breast cancer cells.
We then examined the combination effects of ABT-888 and carboplatin on apoptosis of
MCF7 cells and individually HP1-depleted MCF7 cells. Carboplatin is an alkylating agent that
exhibits a cytotoxic effect on cancer cells by binding to DNA and forming interstrand cross-
links that block DNA replication. Previously, the synthetic lethality of ABT-888 and carbopla-
tin in breast cancer cells with respect to BRCA status was reported in vitro and in vivo [27]. To
test the effect of HP1 status on the synthetic lethality of these two drugs, MCF7 cells and indi-
vidually HP1-depleted MCF7 cells were treated with a combination of ABT-888 (20 μM) and
carboplatin (20 μM). As shown in Fig. 4C, neither ABT-888 alone, carboplatin alone nor com-
bination had marked effect on rendering Annexin V-positive in MCF7 cells. However, same
amounts of ABT-888 or carboplatin induced cell death of HP1β-depleted MCF7 cells (Fig. 4D).
Notably, combination of ABT-888 and carboplatin resulted in marked cytotoxic effects in
HP1β-depleted MCF7 cells. These results showed that PARP inhibitors and/or carboplatin can
be an effective therapy regimen for patients with breast cancer of no or low HP1β expressors.
Conceivably, HP1α or HP1γ deficiency in tumor tissues can be translated as a predictive mark-
er for breast cancer PARP inhibitor therapy. While HP1α and HP1γ compromised MCF7 cells
showed 2~3 fold higher sensitivity to PARP inhibitor treatment, HP1β deficient cells were
much more sensitive to PARP inhibitor (Fig. 4). In other words, HP1 levels, especially HP1β
deficiency, could be a useful predicative marker for BRCAness for the effective use of
PARP therapy.
Discussion
HP1 is a potential prognostic marker for breast cancer
Identification of novel biomarkers for breast cancer is crucial for predicting cancer prognosis
and therapeutic outcomes [28]. The diverse genetic variations and mutations found in breast
cancers make it difficult to classify those tumors into groups to improve therapeutic guidance.
Therefore, identification of additional molecular signatures of breast cancers will provide a bet-
ter basis for targeted therapy and personalized medicine. Herein, results presented in this study
suggest that high levels of HP1β are a poor prognostic marker for breast cancer outcome
(Fig. 1). Moreover, high HP1 expressors may indicate a group of patients harboring actively
growing breast cancer cells, since all HP1α, β and γ expression correlated with Ki-67, a surro-
gate marker for cell proliferation (Fig. 3). Lastly, lack-of-HP1β-expression could serve as a pre-
dictive marker to define a breast cancer therapeutic option (Fig. 4).
Previously, several groups have shown that HP1 subtype levels were either decreased or in-
creased in several cancers and tissues [29]. However, the results from analyzing the levels of
HP1α in breast cancers, in general, are still controversial. For example, Kirschmann et al.
showed that expression level of HP1α was decreased in metastatic and aggressive breast cancer
cells [30]. In contrast, another group demonstrated HP1α expression is upregulated in breast
cancer tumor samples [31]. In this study, we analyzed the expression levels of all three types of
HP1 in breast cancer biospecimens by a combined data mining of published microarray data
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Fig 4. PARP inhibitor, ABT-888, induces apoptosis in HP1-depleted breast cancer cells. ABT-888 (20 μM or 200 μM) was used to treat MCF7 and
individually HP1-depleted MCF7 cells for 72 hours. Cells were stained with Annexin V and propidium iodide staining and cell population was analyzed by flow
cytometry. A. Cell death percentage on Y-axis is for the double stained population using Annexin V (FITC-conjugated) and propidium iodide. B. Annexin V
stained cell population was analyzed by flow cytometry. Y axis: cell numbers, X axis: FL1 values (Annexin V). C. HP1β-depleted MCF7 breast cancer cells
are more prone to apoptosis by ABT-888 and carboplatin. Apoptosis of MCF7 and individually HP1-depleted MCF7 cells was determined after treatment of
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and IHC study. Here we show that the mRNA and protein expression levels of HP1 are fre-
quently altered and diverse among breast cancer biospecimens.HP1βmRNA levels are inverse-
ly correlated with survival (OS and DFS) of breast cancer patients (Fig. 1). HP1α protein levels
showed a correlation with several cancer markers including age, p53 status, ER status and Ki-
67 (Table 1 and Fig. 3). However, expressions of all three subtypes of HP1 are frequently regu-
lated in similar manner in cancer cells (Fig. 2). Our results reveal that all three HP1 subtypes
are potentially useful markers for breast cancer prognosis. Notably, expression levels of HP1
showed strong correlation with Ki-67 level in breast cancer samples (Fig. 3). Ki-67 is used as an
indicator to further classify triple negative breast cancers [32]. Analysis of HP1 expression in
cancer patients may also be useful for further analyzing breast cancer molecular subtypes. Pre-
viously other groups showed that breast cancer cells with high HP1α are more prone to cell
cycle progression [31]. This is consistent with our finding showing a positive correlation of
HP1α and cell proliferation marker Ki-67. Furthermore, our study shows that there is a strong
correlation of Ki-67 expression with other HP1 subtypes. Further investigation of the relation
between expression of HP1 subtypes and Ki-67 in other cancers including prostate cancer
could also be worthwhile [33]. Our results together with other reports suggest the potential sig-
nificance of HP1 in breast cancer prognosis and thus this warrants additional studies.
Potential roles of HP1 in carcinogenesis
While the complicated HP1 levels and pattern in breast cancer biospecimens could also reflect
the heterogeneity of cancer cells in human breast tumors [6, 34], it is intriguing that expression
levels of three HP1 subtypes were comparably regulated in some breast cancer cells. These al-
tered and heterogeneous staining patterns also implicate that HP1 family plays diverse roles in
breast cancers. As HP1 subtypes elicit multiple functions in cells, we surmise that the expres-
sion levels and subcellular location of HP1 are dynamically regulated during tumorigenesis
(Fig. 5). Previously we showed that HP1 is required for homologous recombination repair and
cell cycle control through the regulation of BRCA1 [17]. HP1 is also involved in the other
cellular functions, such as transcription and cell proliferation. Thereby, we speculate that the
lack-of-HP1-expression in some breast cancer tumors can deregulate their BRCA1 functions in
homologous recombination repair and cell cycle checkpoint control. Conceivably, genomic
mutations could accumulate in cancer cells with low HP1 levels. This could explain why some
cancer patients exhibited lack-of-HP1-expression phenotypes in cancer cells.
However, it is not clear how high HP1 expression contributes to tumorigenesis. High levels
of HP1 may deregulate the expression of genes involved in tumorigenesis, thereby promoting
the growth and proliferation of cancer cells. This possibility is supported by the observation
showing a significant correlation of HP1 expression with Ki-67 level (Fig. 3, Table 1, S1, S2 Ta-
bles). Ki-67 is a nuclear protein that correlates with cell cycle progression through S-phase
[35]. It is widely held that Ki-67 exists at low levels in normal and resting (G0 phase) cells. This
is why Ki-67 is considered to be a surrogate marker for cell proliferation and also a poor prog-
nostic marker for several cancers, including breast cancer [36–40]. More recently, HP1γ and
Ki-67 levels in prostate cancer cases were correlated [33]. We propose that high HP1 expres-
sion can be used as a breast cancer marker like Ki-67, indicating actively growing cancer cells,
as does Ki-67. This possibility is supported by several reports demonstrating that HP1 forms a
ABT-888 (20 μM), carboplatin (20 μM) or ABT-888/carboplatin combination (20 μM/20 μM) for 72 hours. A representative Annexin V staining of MCF7 and
HP1β depleted MCF7 cells. D. Percentage of apoptotic MCF7 and HP1-depleted MCF7 cells were determined by double staining with Annexin V and
propidium iodide followed by analysis using flow cytometry. *: p< 0.05 from analysis of three independent assays, Student's t-test.
doi:10.1371/journal.pone.0121207.g004
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complex with Ki-67 through the C-terminal domain of Ki-67 [41, 42]. It is likely that the HP1
and Ki-67 complex is regulated simultaneously and plays critical roles in tumorigenesis.
HP1β is a potential predictive marker for PARP inhibitor therapy
Importantly, our results shown in Fig. 4 clearly suggest that ABT-888, a PARP inhibitor, is
more effective in removing low HP1-expressing, especially low HP1β-expressing, breast cancer
cells by apoptosis. Conceivably, we propose that PARP inhibitor therapy could be an effective
therapy not only for patients with BRCA1/2 mutations but also for patients with no/low HP1β
expressions. However, it is not clear what is the therapeutic recommendation for breast cancer
groups with high HP1 expression. It is possible that HP1-high patient group could benefit
from either combination therapy of PARP inhibitor/epigenetic drugs or alternative therapy
(Fig. 5). Alternative therapeutic strategies could be a better option for breast cancer patients
Fig 5. HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.Respective HP1 expression level is frequently altered in breast
cancer cells, suggesting the diverse role of each HP1 subtype in breast cancers. This model shows that the expression level of HP1 subtype in breast cancer
cells may be either decreased or increased according to cancer stage, grade, cancer cell proliferation (Ki-67) and aggressiveness. PARP inhibitor therapy
may be an effective therapy for patients with no/low HP1β expression. Combination therapy with epigenetic drugs (including H3K9 methylation inhibitors) or
alternative therapy is necessary for patients with breast cancers of high HP1 abundance.
doi:10.1371/journal.pone.0121207.g005
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with high HP1 expression. Since HP1 plays critical roles in heterochromatin maintenance, we
further speculate that the effects of high HP1 abundance in cancer cells to be overcome by
drugs affecting chromatin structure including HDAC (histone deacetylase) inhibitors or H3K9
(histone H2 Lysine 9) methylation inhibitors.
One of the caveats of PARP inhibitor therapy is the selectivity of the drug in killing particu-
lar cancer cells [12, 13]. PARP inhibitor can selectively kill BRCA1-deficient and HR-repair de-
ficient cancer cells [10]. PARP therapy could be an important therapeutic option for breast
cancer, ovarian cancer and other cancers and clinical trials of PARP inhibitor are currently in
progress [14–16]. One of the limitations of PARP therapy is that there are limited numbers of
cancer patients with BRCA1 or BRCA2 mutation. If this experimental finding holds in pre-
clinical or clinical studies, many more breast cancer patients could benefit from PARP inhibitor
therapy, because HR repair is deficient in many cancers without BRCA1 or BRCA2 mutations.
This so-called BRCAness phenomenon was reported previously in breast, ovarian and other
cancer cases [9, 15, 43–45]. Impaired homologous recombination repair can be caused by epi-
genetic DNA methylation of promoters or by mutations of DNA damage response regulators
[9]. Since we showed that HP1-deficiency impaired homologous recombination repair and ren-
dered BRCAness phenotype in breast cancer cells [17], we confirmed the cytotoxicity of PARP
inhibitor for HP1-deficient breast cancer cells (Fig. 4). To the best of our knowledge, there is
no standard assay to detect BRCAness [15]. This study indicates that analysis of HP1β expres-
sion level can be an informative predictive biomarker for BRCAness and for inducing synthetic
lethality of breast cancer cells by PARP inhibition. Thus, analysis of HP1β level in breast tu-
mors not only provides a breast cancer prognosis biomarker but also a predictor for PARP
inhibitor therapy.
Supporting Information
S1 Fig. IHC scoring standard for breast cancer samples. Breast cancer samples were stained
with an anti-HP1β antibody. IHC scores of each breast cancer samples were scored according
to the intensity of staining. This standard staining 0 shows no staining by HP1β. Standard 3
shows the strong staining. IHC scoring was performed according to this staining standard.
(TIF)
S2 Fig. Western blot analysis for MCF7 and HP1-depleted MCF7 cells by HP1-specific anti-
bodies.MCF7 cells were infected with lentiviral vectors harboring shRNAs for each HP1 sub-
types [17]. Knockdown efficiency of HP1 in MCF7 cells are analyzed by Western blot with
specific HP1 antibodies.
(TIF)
S1 Table. Contingency analysis of HP1α in breast cancer samples.
(DOCX)
S2 Table. Contingency analysis of HP1γ in breast cancer samples.
(DOCX)
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